Drug Database
AL

albumin (albumin, Qiombiotec)

✓ Approved

Quimbiotec · Cell-based Therapies · Cell-based Therapies

What is albumin?

albumin is a cell-based therapies developed by Quimbiotec. It is approved for therapeutic indications via injectable (others) or intravenous (iv).

Drug Profile

Brand Namesalbumin, Qiombiotec
CompanyQuimbiotec
Drug ClassCell-based Therapies
RouteInjectable (Others), Intravenous (IV)
StatusApproved

Therapeutic Indications

albumin is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Metabolism and nutrition disordersHypoalbuminaemia✓ Approved

Related Research Articles

PubMedFrontiers in medicine2026-11-12

Postoperative hypoalbuminemia, albumin supplementation, and short-term complications after radical gastrectomy in elderly gastric cancer patients.

Guan Yu-Nan YN, Lin Xiao-Ming XM, Liu Xue-Lian XL, Guo Yu-Chen YC et al.

To examine the association between early postoperative hypoalbuminemia and complications within 30 days after radical gastrectomy in older patients with gastric cancer, and to further explore the association between postoperative albumin supplementation and short-term outcomes among patients who developed hypoalbuminemia. This single-center retrospective cohort study included 378 elderly patients who underwent radical gastrectomy for gastric cancer at the First Hospital of Jilin University from January to December 2023. Patients were classified into a hypoalbuminemia group (<30 g/L) and a normal albumin group (>=30 g/L) according to the lowest serum albumin level within the first 7 postoperative days. The primary outcome was Clavien-Dindo grade >=3 complications within 30 days after surgery, and the secondary outcome was Clavien-Dindo grade >=2 complications and postoperative length of stay. Covariates in the main adjusted models were prespecified on the basis of clinical relevance. Firth penalized logistic regression was used for the primary outcome because of the limited number of events, whereas conventional logistic regression was used for Clavien-Dindo grade ≥2 complications. Postoperative nadir albumin was also examined as a continuous variable. Among patients with hypoalbuminemia, propensity score matching was used to explore the association between postoperative albumin supplementation and short-term outcomes. A POD1 landmark sensitivity analysis was additionally performed to reduce temporal overlap between postoperative albumin assessment and complication occurrence. Among the 378 patients, 246 were classified into the hypoalbuminemia group and 132 into the normal albumin group. The incidence of Clavien-Dindo grade ≥3 complications was higher in the hypoalbuminemia group than in the normal albumin group (15.9% vs. 2.3%, P < 0.001). After adjustment for age, body mass index, American Society of Anesthesiologists physical status, preoperative serum albumin, surgical approach, surgical method, intraoperative blood transfusion, and pathological TNM stage, postoperative hypoalbuminemia remained associated with Clavien-Dindo grade ≥3 complications (adjusted OR, 4.51; 95%CI, 1.55-17.54; P = 0.004). When postoperative nadir albumin was modeled continuously, each 5-g/L decrease was associated with an adjusted OR of 4.71 (95%CI, 2.43-9.51; P < 0.001). The incidence of Clavien-Dindo grade ≥2 complications was also higher in the hypoalbuminemia group (61.8% vs. 24.2%, P < 0.001). The corresponding adjusted ORs were 3.75 (95%CI, 2.16-6.62; P < 0.001) for the categorical model and 4.21 (95%CI, 2.54-7.21; P < 0.001) per 5-g/L decrease in postoperative nadir albumin. Postoperative length of stay was longer in the hypoalbuminemia group [6.0 (5.0-9.0) d vs. 5.0 (4.0-6.0) d, P < 0.001]. In the POD1 landmark sensitivity analysis, the associations were attenuated. Lower POD1 serum albumin remained associated with Clavien-Dindo grade ≥2 complications in both the categorical model (adjusted OR, 1.90; 95%CI, 1.09-3.34; P = 0.024) and the continuous model (adjusted OR per 5-g/L decrease, 2.08; 95%CI, 1.36-3.22; P < 0.001), whereas the associations with grade ≥3 complications were no longer statistically significant. After 1:1 propensity score matching, 154 patients with hypoalbuminemia were included, with 77 patients in each supplementation group. Conditional logistic regression accounting for the matched-pair structure showed an association between recorded postoperative albumin supplementation and Clavien-Dindo grade ≥2 complications (OR, 2.00; 95%CI, 1.12-3.58; P = 0.020). Lower serum albumin levels during postoperative days 1-7 were associated with Clavien-Dindo grade ≥3 and grade ≥2 complications within 30 days after radical gastrectomy in older patients with gastric cancer. However, these associations were attenuated in the POD1 landmark sensitivity analysis, particularly for grade ≥3 complications, highlighting the potential influence of temporal overlap and reverse causation. Because the albumin assessment window overlapped with the complication surveillance period, the main findings should be interpreted as associations rather than evidence of temporal sequence or causality. Among patients with hypoalbuminemia, recorded postoperative albumin supplementation was not associated with a lower incidence of complications; this finding may have been influenced by confounding by indication, residual confounding, and reverse causation. Postoperative assessment should therefore consider surgical trauma, inflammatory response, volume status, and overall recovery rather than relying on a single serum albumin value.

PubMedCritical care (London, England)2026-11-12

Early albumin use and mortality in critically III children with severe hypoalbuminemia: a target trial emulation study.

Zhang Yu-Zhen YZ, Xie Chao C, Nie Meng-Sha MS, Sun Jing-Jing JJ et al.

Hypoalbuminemia is highly prevalent in critically ill children and is an established independent risk factor for mortality. Whether albumin supplementation is associated with improved survival remains unclear, particularly in pediatric populations where causal evidence is sparse. This retrospective cohort study used data from the Pediatric Intensive Care (PIC) database, a single-center pediatric-specific critical care database in China, and adopted a target trial emulation (TTE) framework. Children whose first albumin measurement within 24 h of ICU admission was below 30 g/L were included (N = 1,649). Time zero was defined as the first detection of albumin below 30 g/L. The exposure was receipt of at least one dose of human albumin within 24 h after time zero. Primary outcomes were 7-day and 28-day all-cause mortality, estimated using IPTW-weighted Cox proportional hazards models with doubly robust adjustment. Sensitivity to unmeasured confounding was assessed by E-value. Among 1,649 children, 374 (22.7%) received early albumin therapy. After doubly robust adjustment, early albumin therapy was associated with reduced 7-day mortality (HR, 0.42; 95% CI, 0.24-0.74; P = 0.003; E-value = 4.21). The association with 28-day mortality was not significant (HR, 0.79; 95% CI, 0.45-1.36; P = 0.393). Relaxing the hypoalbuminemia threshold to below 35 g/L attenuated the 7-day association (HR, 0.64; 95% CI, 0.39-1.05). Extending the treatment window to 48 h further attenuated the association (HR, 0.87; 95% CI, 0.40-1.91). A significant interaction was observed between vasoactive agent use and albumin therapy (P for interaction = 0.045), with the strongest association among children not receiving vasoactive agents (HR, 0.17; 95% CI, 0.04-0.70). In critically ill children with severe hypoalbuminemia, early albumin therapy was associated with reduced 7-day mortality. This association showed clear threshold- and time-dependence, suggesting that any potential benefit may concentrate within a narrow clinical window early in the disease course. Prospective confirmation is needed. Not applicable. This is a retrospective observational study using de-identified data; the study protocol was not prospectively registered in a clinical trials registry.

PubMedCureus2026-11-12

Current Approaches to the Treatment of Hepatorenal Syndrome.

Rosales César A CA

Hepatorenal syndrome (HRS) is a life-threatening complication of advanced cirrhosis that requires early recognition, treatment of precipitating factors, and coordinated transplant assessment. This narrative review examines pharmacological treatment, fluid management, kidney replacement therapy (KRT), transjugular intrahepatic portosystemic shunt (TIPS), and liver transplantation in adults, with emphasis on HRS with acute kidney injury (AKI). Contemporary diagnostic criteria recognize that hepatorenal physiology can coexist with tubular injury or chronic kidney disease (CKD) and discourage a routine 48-hour albumin challenge. Clinical assessment should integrate perfusion, oxygenation, and congestion, with ultrasound used as an adjunct when available. Terlipressin with individualized albumin improves renal reversal in suitable patients, but a consistent overall survival benefit has not been established, and respiratory failure remains a major safety concern. Norepinephrine is an important alternative where appropriate monitoring is available; midodrine with octreotide has a limited fallback role. Albumin dosing should reflect serial volume assessment rather than a serum albumin target. Kidney replacement therapy supports patients with metabolic or volume complications, while evidence for routine shunt placement in acute HRS remains insufficient. Liver transplantation addresses the underlying disease, although kidney recovery is variable. Biomarkers may assist clinical phenotyping, but their use to guide treatment requires prospective validation. The review emphasizes timely diagnosis, individualized treatment, and distinguishing renal recovery from survival.

PubMedThe journal of physical chemistry letters2026-11-12

Spectroscopic and Computational Insights into Different Binding with Bovine Serum Albumin and Esterase-Like Activity Tuning: Echinatin versus Licochalcone B.

Li Dehui D, Guo Yiming Y, Tian Hu H, Bai Yunpeng Y et al.

The interactions of two chalcones, echinatin (ECN) and licochalcone B (LCB), differing by a single B ring phenolic-OH, with bovine serum albumin (BSA) and their modulation of BSA esterase-like activity were investigated spectroscopically and via molecular docking under physiological conditions. UV-vis absorption, fluorescence, and competitive displacement assays revealed both ligands form ground-state complexes with BSA at Sudlow Site I. Thermodynamics showed spontaneous, exothermic binding driven by hydrogen bonds and van der Waals forces. Raman and docking indicated ECN binds via its A ring and carbonyl, whereas LCB binds via its B ring and carbonyl. This subtle structural difference yields distinct binding modes, underlying their differing modulation of BSA esterase-like activity, with LCB being a stronger enhancer. These findings reveal how a single hydroxyl difference tunes albumin recognition and activity regulation, shedding light on their pharmacological and pharmacokinetic divergence while guiding the design of licorice-derived chalcones.

PubMedDiseases of the colon and rectum2026-11-12

C-Reactive Protein to Albumin Ratio as a Rule Out Predictor For Organ/Space Infections After Ileocolic Resection in Crohn's Disease.

Pepe Filippo F, Mineccia Michela M, Perotti Serena S, Massucco Paolo P et al.

Organ/space surgical site infections, including intra-abdominal abscesses and anastomotic leaks, are among the most severe complications after ileocolic resection for Crohn's disease. Biomarker cutoffs validated in oncological colorectal surgery may not translate to Crohn's disease because of modified inflammatory responses due to chronic inflammation and immunosuppressive therapies. To identify early predictors of organ/space surgical site infections after ileocolic resection for Crohn's disease and to evaluate the performance of established biomarkers and specific predictive scores. Single-center retrospective observational study. Tertiary referral center utilizing enhanced recovery after surgery pathways. A total of 115 patients with histologically confirmed Crohn's disease. Ileocolic resection with primary anastomosis between January 2021 and May 2025. Development of organ/space surgical site infections within 30 days postoperatively, defined according to Centers for Disease Control/National Helathcare Safety Network criteria. Organ/space surgical site infections occurred in 15.7% (18/115) of patients. The C-reactive protein-to-albumin ratio on postoperative day 3 demonstrated excellent diagnostic accuracy (area under the curve = 0.932). At an optimal cutoff of 51.77, C-reactive protein-to-albumin ratio on postoperative day 3 yielded 94.1% sensitivity, 82.1% specificity, and a negative predictive value of 98.6%. C-reactive protein on postoperative day 3 also showed good accuracy (area under the curve = 0.871) with a negative predictive value of 97.1%. Procalcitonin and leucocyte-based indices showed poor-to-limited discrimination. Retrospective, monocentric design without external validation. In Crohn's disease surgery, C-reactive protein-to-albumin ratio on postoperative Day 3 is a strong early predictor of organ/space surgical site infections. Together with C-reactive protein, its exceptionally high negative predictive value provides high "rule out" utility, supporting postoperative surveillance and safe discharge pathways. (See Video Abstract).

PubMedThe Eurasian journal of medicine2026-11-12

Assessment of C-Reactive Protein/Albumin Ratio and Other Inflammatory Markers in Rosacea: A Case-Control Study.

Soğuksu Ahmet Onur AO, Pala Erdal E

Although rosacea is a persistent inflammatory illness, a specific parameter capable of demonstrating its severity has not been established. This study examined C-reactive protein (CRP) and CRP/ albumin ratio (CAR) levels in rosacea patients, comparing them with those in healthy control groups and investigating their relationship with disease severity. This study is a prospective cross-sectional study. C-reactive protein, albumin, CAR, platelet, neutrophil, lymphocyte, and monocyte levels were measured in patients diagnosed with rosacea who presented to the Dermatology Clinic over a 1-year period. The results were statistically evaluated by comparing them with the values of a healthy control group. The mean CRP level in patients with rosacea was 3.0 ± 3.3 mg/dL and the CAR level was 0.9 ± 0.9. In the control group, these values were 1.8 ± 1.7 mg/dL and 0.58 ± 0.51, respectively. Compared with healthy controls, the rosacea group showed markedly higher CRP and CAR concentrations, supported by significant P-values (.014 and .028). In the receiver operating characteristic analysis, the area under the curve was found to be 0.59 for CRP and 0.58 for CAR. A CRP value above 1.88 mg/dL showed 48.3% sensitivity and 70% specificity, while a CAR value above 0.98 showed 31.6% sensitivity and 88.3% specificity. Elevated CRP and CAR levels support the presence of systemic inflammatory activity in rosacea. Although both CRP and CAR levels are elevated in patients with rosacea, in this study, neither marker showed a significant association with disease severity. According to the study, CRP and CAR may be more meaningful and useful than other classic inflammatory parameters for determining the inflammatory burden in patients with rosacea. Cite this article as: Soğuksu AO, Pala E. Assessment of C-reactive protein/albumin ratio and other inflammatory markers in rosacea: a case-control study. Eurasian J Med. 2026, 58(4), 1468, doi: 10.5152/eurasianjmed.2026.261468.

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about albumin